Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of XW10172 Formulations in Healthy Volunteers
NCT04688580Phase 1Completed
- Sponsor
- XWPharma
- Start
- Nov 2020
- Primary completion
- Dec 2021
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of valiloxybate in narcolepsy and Parkinson's disease (PD), sponsored by XWPharma. Primary endpoints: Maximum concentration at 12 hours, Trough concentration at 12 hours and 7 more. Started Nov 2020; status: completed.
02
Drugs
valiloxybate
03
Conditions
narcolepsyParkinson's disease (PD)
Beyond the preview
Go deeper on NCT04688580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04688580.